Cerenovus, a neurovascular company that is part of the Johnson & Johnson Medical Devices Companies, announced the launch of Emboguard, its next-generation balloon guiding catheter for use in endovascular procedures, including those for patients with acute ischemic stroke. .
Emboguard is designed to optimize blood clot removal by locally controlling blood flow during mechanical thrombectomy procedures. According to a press release from Cerenovus, which also states that distal emboli during an endovascular procedure can lead to new ischemic events, balloon guide catheters increase first-pass recanalization, reduce procedure time and reduce risk. rupture of clot fragments and causing distal embolisms.
“Without prompt and effective stroke treatment, patients can suffer lifelong disability or addiction,” said David Fiorella (Stony Brook University Hospital, New York, USA). “The benefits of balloon guide catheters are increasingly recognized for their ability to maximize patient outcomes. By adding this innovation to its portfolio of stroke solutions, Cerenovus will provide physicians with the tools they need to better serve our patients, potentially increasing the chances of living a functional and fulfilling life after stroke.
Emboguard is the latest addition to Cerenovus Stroke Solutions, a suite of technologies designed with compatibility in mind to help physicians perform mechanical thrombectomy procedures. Launched in 2020, it now includes the Embotrap III Revascularization Device, Prowler Ex Microcatheter and Cerenovus Large Bore Catheter as well as the Emboguard Balloon Guide Catheter and Cerebase Guide Sheath.
The Emboguard Balloon Guide Catheter is set to debut for the first time at the International Stroke Conference (ISC 2022; February 9-11, New Orleans, USA).